Wuhan Hiteck Biological Pharma Co (SZSE:300683) Total Current Assets : ¥1,198.9 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Wuhan Hiteck Biological Pharma Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Wuhan Hiteck Biological Pharma Co's total current assets for the quarter that ended in Mar. 2025 was ¥1,198.9 Mil.

Wuhan Hiteck Biological Pharma Co Total Current Assets Historical Data

The historical data trend for Wuhan Hiteck Biological Pharma Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hiteck Biological Pharma Co Total Current Assets Chart

Wuhan Hiteck Biological Pharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

1,327.90

1,582.52

1,444.13

1,488.20

1,306.33

Wuhan Hiteck Biological Pharma Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															1,470.63	1,323.79	1,320.77	1,306.33	1,198.93

Wuhan Hiteck Biological Pharma Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Wuhan Hiteck Biological Pharma Co's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	868.84	+	307.606	+	108.981	+	20.906
	=	1,306.3

Wuhan Hiteck Biological Pharma Co's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	754.301	+	305.36	+	109.92	+	29.351
	=	1,198.9

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Wuhan Hiteck Biological Pharma Co (SZSE:300683) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Wuhan Hiteck Biological Pharma Co's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	754.301	-	423.896	+	0.75 * 57.038	+	0.5 * 109.92
=	428.1

Wuhan Hiteck Biological Pharma Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Wuhan Hiteck Biological Pharma Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuhan Hiteck Biological Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Wuhan Hiteck Biological Pharma Co Ltd (SZSE:300683) » Definitions » Total Current Assets

Traded in Other Exchanges

N/A

Address

Hite Science and Technology Park, Wuhan Economic and Technological Development Zone, Hubei Province, Wuhan, CHN, 430056

Website

http://www.hiteck.com.cn

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.

Executives

Yan Jie	Director
Li Sheng Qiang	Executives

Wuhan Hiteck Biological Pharma Co Headlines

No Headlines